Armaviskon forte solution for intra-syst. Introduction. 2.3%, 3 ml No. 1 syringe

• To increase the mobility of the joint and eliminate pain caused by degenerative-dystrophic or post-traumatic changes in the joints;

• For rehabilitation after arthroscopy;

• For the treatment of patients with increased physical activity and regularly loading the affected joint.

Intra-articular. In the knee joint, the contents of one filled syringe - 3 ml (69 mg).

1 injection is required per course of treatment according to the standard method described below.

Typically a 1.5 '' 21G needle is used for the knee joint, for other joints it is recommended to use the correct size needle (17G to 22G) depending on the joint.

Method of administration: The agent should be administered only by specially trained medical personnel. The mode of introduction into the hip and other joints is determined by the doctor individually, taking into account the severity of degenerative or traumatic changes in the joint. It is recommended to perform injections into the hip and other joints under ultrasound or fluoroscopic guidance.

It is recommended to warm the product to room temperature before use. The agent should be injected exactly into the joint cavity according to standard techniques, taking into account the anatomical features. Before the introduction of the agent, the effusion should be removed from the joint capsule. The same needle, once inserted prior to aspiration, can be used to remove effusion and administer the agent. In this case, the syringe with the agent is attached to the needle released from the syringe.

To confirm that the needle is in the joint cavity, the available amount of synovial fluid should be aspirated before slow injection. You should follow the rules of asepsis and antiseptics when performing the procedure. The introduction of the drug into the joint cavity should be stopped if pain occurs during the injection. When inserting a needle, especially for injections into the hip joint, the use of local anesthesia is recommended. Avoid getting air into the syringe.

The product that has not been used up to the end cannot be stored.

The duration of the therapeutic effect is up to 6 months. If necessary, it is possible to carry out a repeated course of injections after consulting a doctor.

Composition for 1 ml:

sodium hyaluronate - 20.7-25.3 mg / ml (2.3%),

sodium chloride - 8.55 mg / ml,

sodium hydrogen phosphate dihydrate - 0.33 mg / ml,

sodium dihydrogen phosphate dihydrate - 0.060 mg / ml,

water for injection - up to 1 ml.

• Hypersensitivity to the components of the product; the presence of infection or damage to the skin in the area of ??injection;

• acute synovitis;

• children under 18 years of age (due to lack of clinical data).

• Application during pregnancy and during breastfeeding: It is not recommended to use the drug during pregnancy and during breastfeeding due to the lack of clinical data. Prescription of the drug during pregnancy and during breastfeeding at the discretion of the orthopedic surgeon.

pharmachologic effect

The agent that affects the phosphorus-calcium metabolism in the cartilage tissue is a high molecular weight mucopolysaccharide. It slows down the resorption of bone tissue and reduces calcium loss, accelerates the processes of bone tissue repair, inhibits the process of degeneration of cartilage tissue. It prevents the compression of connective tissue and plays the role of a kind of lubrication of the articular surfaces. When applied externally, it slows down the progression of osteoarthritis. Normalizes metabolism in hyaline tissue. Stimulates the regeneration of articular cartilage.

Pharmacokinetics

With a single oral administration of an average therapeutic dose, Cmax in plasma is achieved after 3-4 hours, in synovial fluid - after 4-5 hours. Bioavailability is 13%. It is excreted by the kidneys within 24 hours.

Side effect

Rarely: allergic reactions.

Application during pregnancy and lactation

Chondroitin sulfate is contraindicated for use during pregnancy and lactation (breastfeeding).

Use in elderly patients

There are clinical data on the use of chondroitin sulfate in elderly patients with atherosclerosis, with a slight decrease in the concentration of cholesterol and triglycerides in the blood plasma.

special instructions

With various forms of periodontal disease, the course of treatment should be continued for at least 3 months.

There are clinical data on the use of chondroitin sulfate in elderly patients with atherosclerosis, with a slight decrease in the concentration of cholesterol and triglycerides in the blood plasma.